Apr 15 |
Mustang Bio stock tumbles 27% amid news of mass layoffs
|
Mar 28 |
Mustang Bio stock climbs 9% amid drug development update
|
Mar 28 |
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
|
Mar 15 |
Mustang Bio files to sell common stocks, warrants, no amount given
|
Mar 11 |
Mustang Bio GAAP EPS of -$6.00 beats by $0.67
|
Mar 11 |
Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
|
Mar 7 |
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma
|
Jan 11 |
Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
|
Dec 12 |
Mustang Bio files to sell 2.74M shares of common stock for holders
|
Dec 11 |
Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting
|